Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering EDINBURGH, United Kingdom , Oct. 13, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the
Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302) NUC-3373’s Favorable Pharmacokinetic and Safety Profile Unaffected by Leucovorin First-in-Human Data of NUC-7738 Shows Anti-Cancer Activity and a
EDINBURGH, United Kingdom , Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the closing of its previously announced underwritten public offering of 17,888,889
EDINBURGH, United Kingdom , Sept. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the pricing of an underwritten public offering of 15,555,556 American Depositary Shares
EDINBURGH, United Kingdom , Sept. 16, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that it has commenced an underwritten public offering of its American Depositary
EDINBURGH, United Kingdom , Aug. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
EDINBURGH, United Kingdom , May 27, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference .
Clinical Studies Re-Opened to New Patient Enrollment Following Temporary Pause Due to COVID-19 Pandemic Numerous Clinical Data Announcements Expected in 2020 Cash and Cash Equivalents Expected to Fund Operations At Least into the Fourth Quarter of 2021 EDINBURGH, United Kingdom , May 19, 2020
EDINBURGH, United Kingdom , May 18, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in multiple clinical studies following the temporary pause necessitated by the COVID-19 pandemic. NuCana previously announced the re-opening of its global
Non-Clinical Findings Suggest that Acelarin and NUC-3373 May Induce an Immune Response Against Cancer Cells Acelarin (NUC-1031) Releases DAMPs and Upregulates PD-L1 Expression in Lung Cancer Cells NUC-3373 Induces Endoplasmic Reticulum Stress and Release of DAMPs in Colorectal Cancer Cells
